What is the common age group for the late stage of age-related macular degeneration (AMD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common Age Group for Late-Stage AMD

Late-stage age-related macular degeneration predominantly affects individuals aged 85 years and older, with this age group showing a 10-fold higher prevalence compared to those in their early 70s. 1

Age Distribution and Prevalence

The prevalence of late AMD increases dramatically with advancing age:

  • Individuals aged 85+ years have the highest burden, with exudative (wet) AMD affecting 11.4% and pure geographic atrophy (dry) affecting 7.6% of this population 1

  • The disease affects individuals over 55 years, though late-stage manifestations are uncommon until significantly older ages 2, 3

  • Among those aged 66-74 years, late AMD prevalence is substantially lower, demonstrating the steep age-related increase in disease severity 1

Clinical Context

Late AMD encompasses two forms that cause severe, often irreversible vision loss:

  • Neovascular (wet) AMD characterized by macular neovascularization with fluid accumulation 2

  • Geographic atrophy (dry AMD) marked by progressive atrophy of the retinal pigment epithelium and outer retinal layers 2

Both forms can coexist in the same patient and typically present with profoundly decreased central vision affecting both eyes at this advanced stage 2

Public Health Implications

The concentration of late AMD in the oldest age groups (85+ years) has critical implications:

  • With global aging populations and increased longevity, the number of people with AMD worldwide is predicted to increase from 196 million in 2020 to 288 million by 2040 2

  • The 10-fold higher prevalence in the oldest cohort compared to younger elderly patients underscores the need for improved preventive measures and novel treatments 1

  • AMD remains the leading cause of blindness in individuals over 65 years in Western countries 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.